Illumina (ILMN)

Illumina’s core business is built around sequencing systems and the recurring sale of consumables used to run those systems. High-throughput platforms support large-scale projects that require vast amounts of genetic data, while benchtop and lower-throughput instruments serve laboratories focused on targeted testing or smaller sample volumes. The company also sells microarray products, which provide a lower-cost way to examine selected genetic markers and remain useful in consumer genetics, agricultural screening, and focused research applications.

The company’s competitive position rests on its installed base, sequencing chemistry, data quality, workflow integration, and broad ecosystem of compatible assays and analysis tools. Customers include academic institutions, government research bodies, hospitals, reference laboratories, pharmaceutical companies, and biotechnology firms. As genomics becomes more embedded in clinical care, Illumina is exposed to long-term demand for faster, cheaper, and more accurate genetic analysis.

For investors, ILMN is closely tied to adoption trends in life sciences research and molecular diagnostics, as well as funding conditions for laboratories and biotech customers. Its growth depends on new platform cycles, consumable pull-through, clinical market expansion, pricing discipline, and competition from alternative sequencing technologies.